摘要
目的分析变应性鼻炎(AR)皮下特异性免疫治疗(SCIT)患者中断治疗的原因,并提出干预措施。方法2014年12月~2019年12月我院鼻科共有249例对尘螨过敏的中重度持续性AR患者结束了SCIT,通过总结病史资料分析患者结束SCIT的原因。结果162例患者中断治疗,未成年组中断率显著低于成年组(55.56%vs 72.34%;χ^(2)=7.580,P<0.01);起始治疗阶段中断治疗54例(33.33%),维持治疗阶段中断治疗108例(66.67%)。中断治疗的原因主要与疗效相关,其中患者自认为过敏症状好转而自行终止治疗占比最高,为29.63%(48例),其次为因治疗效果不明显而结束治疗,占24.07%(39例)。结论SCIT的中断率较高,成年人中断率高于未成年人,维持治疗阶段是中断的高发阶段。对有中断倾向的患者提出针对性的干预措施有利于降低SCIT的中断率,从而提高治疗效果。
Objective To analyze the causal factors of discontinued subcutaneous specific immunotherapy(SCIT)among allergic rhinitis(AR)patients and to propose interventions.Methods Two hundred and forty-nine patients with moderate to severe persistent AR allergic to dust mite in the Department of Rhinology of our hospital from December 2014 to December 2019 ended SCIT.The causes of interrupting SCIT were analyzed.Results One hundred and sixty-two patients discontinued SCIT.The interruption rate in the juvenile group was significantly lower than that in the adult group(55.56%vs 72.34%;χ^(2)=7.580,P<0.01).There were 54(33.33%)patients who had discontinued SCIT during the initial stage and 108(66.67%)patients during the maintenance stage.The reason for discontinuing SCIT was mainly related to the therapeutic effect.The highest proportion of patients who thought that their allergic symptoms had improved and terminated SCIT on their own was 29.63%(48 cases),followed by 24.07%(39 cases)patients who thought that the therapeutic effect was not obvious.Conclusions The interruption rate of SCIT was high,which was higher among adults than among adolescents.Discontinuance happened more frequently in the maintenance stage.Targeted interventions for patients with interruption tendency will be helpful to reduce the interruption rate of SCIT and improve the treatment effect.
作者
冯仙
刘娟
FENG Xian;LIU Juan(Department of Otolaryngology,Eye&ENT Hospital,Fudan University,Shanghai 200031,China)
出处
《中国眼耳鼻喉科杂志》
2022年第3期232-235,共4页
Chinese Journal of Ophthalmology and Otorhinolaryngology
关键词
变应性鼻炎
皮下特异性免疫治疗
依从性
Allergic rhinitis
Subcutaneous specific immunotherapy
Compliance
